§ Federal grant opportunity · RFA-DA-25-060
High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
National Institutes of Health is accepting applications for High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional). The deadline is March 5, 2027 and the published award range is $1.5M.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- March 5, 2027
- Award range
- $1.5M
- Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Geography
- United States
- Focus areas
- Education, Health
- Opportunity number
- RFA-DA-25-060
Program overview
The purpose of this Funding Opportunity Announcement (FOA) is to support high priority research at the intersection of HIV and substance use. This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). Applications submitted under this FOA are required to have a detailed research plan, preliminary data, and a clear description of the nexus with substance use. This FOA is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research. All studies must focus on NIH HIV/AIDS Research Priorities: NOT-OD-20-018: UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before March 5, 2027, allowing time for registration and validation.
Related grant opportunities
- Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)
- High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
- NEA Arts and Artifacts International Indemnity Program 2, FY2027 (3/27)
- Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.